Soligenix Inc. has secured a positive recommendation from the European Medicines Agency's Committee for Orphan Medicinal Products for orphan drug designation of dusquetide (SGX945) as a treatment for Behçet's Disease. The backing represents a significant regulatory milestone for the biopharmaceutical company, building on earlier clinical validation of the candidate therapy.
The positive opinion follows encouraging Phase 2a clinical trial results that demonstrated biological efficacy and a favorable safety profile for SGX945 in Behçet's Disease patients. The designation aligns with prior regulatory support from the U.S. Food and Drug Administration, which previously granted both orphan drug and fast track designations for the same indication, indicating accelerated development pathways in multiple major markets.
Orphan drug designation in the European Union provides qualifying treatments with ten years of marketing exclusivity following approval, a standard incentive designed to encourage development of therapies for rare diseases. The EMA's Committee for Orphan Medicinal Products recommendation strengthens Soligenix's regulatory position as the company advances SGX945 through clinical development.